Biomarin Pharmaceutical EV/EBIT BMRN

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2016.

Today, Oct 23, 2026: 25.8×
10-year median: 73.5×
Against its 10-year history: 27th; percentile: 0 is its lowest day, 100 its highest
10-year range: 10.7× to 494×
Peer median: 57.7×

Biomarin Pharmaceutical's EV/EBIT is 25.8× as of Oct 23, 2026.

That is below its ten-year median of 73.5×, lower than on 73% of days in the last ten years.

Over that time it ranged from 10.7× in Nov 2025 to 494× in May 2022.

The median for 10 large drugmakers of a similar size is 57.7×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	25.8×	11.5×	29.8×
2025	12.7×	10.7×	32.0×
2024	31.4×	29.7×	124×
2023	124×	102×	207×
2022	176×	139×	494×
2021	n/m a value too high to mean anything
2020	231×	223×	397×
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	79.5×	76.8×	81.9×
2016	75.1×	74.3×	215×

Against its peers

Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.

Company	EV/EBIT
BMRNBiomarin Pharmaceutical	25.8×
CORTCorcept Therapeutics	n/m
PTGXProtagonist Therapeutics	140×
JAZZJazz Pharmaceuticals	15.9×
TGTXTG Therapeutics	62.2×
ALKSAlkermes plc.	69.6×
AMRXAmneal Pharmaceuticals	18.3×
LGNDLigand Pharmaceuticals	57.7×
KNSAKiniksa Pharmaceuticals International	54.6×
INDVIndivior Pharmaceuticals	7.8×
ARQTArcutis Biotherapeutics	111×
Peer median	57.7×

Where Biomarin Pharmaceutical ranks

#35of 48Large drugmakers with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Biomarin Pharmaceutical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.